Lysogene announced on Friday that it was looking for a buyer or investor, with the official opening of receivership proceedings.

The biopharmaceutical company, which specializes in gene therapies, said it had applied, together with its receiver, to convert the safeguard procedure it had been under since last December into receivership proceedings.

The Nanterre Commercial Court is due to rule on the application in the next few days.

The company justifies this decision by the fact that the safeguard procedure did not enable it to identify a solution to consolidate its financial situation, nor to perpetuate its financing horizon.

In this context, a call for bids to find buyers or investors has been published, with a deadline for submission of bids set for February 15.

In the meantime, its share price remains suspended on the Paris stock exchange.

Copyright (c) 2023 CercleFinance.com. All rights reserved.